MetaCap

Milestone Pharmaceuticals (MIST) vs Nomad Power Solutions (NMAD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nomad Power Solutions (NMAD) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 40.6% versus a loss of 84.5%. Over five years, NMAD leads with a -84.6% price change compared with -93.8% for MIST. Nomad Power Solutions is the larger company by market cap ($47.2 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIST-84.54%NMAD-40.60%
+95%+1%-93%
Nov 21, 20251 yearNov 20, 2026
MIST-93.88%NMAD-85.12%
+64%-20%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIST versus NMAD key metrics
MetricMISTNMAD
Share price$0.3711$2.56
Market cap$46.20M$47.15M
1-day change-7.06%+13.53%
YTD return-81.63%-34.86%
1-year return-84.54%-40.60%
5-year return-93.85%-84.58%
EPS (TTM)$-0.74$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-63.06M$-6.08M
52-week high$3.06$8.38
52-week low$0.362$2.13
Distance from 52-week high-87.87%-69.45%
Analyst consensusnone—
Avg. price target upside+1479.09%—
Average volume1.53M228.96K
Shares outstanding124.50M18.42M
Employees38—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NMAD has outperformed MIST by 43.9 percentage points over the past year.

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Nomad Power Solutions

NMAD stock →

NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.

Health Care · Biotechnology: Pharmaceutical Preparations

MIST vs NMAD FAQ

Which is bigger, Milestone Pharmaceuticals or Nomad Power Solutions?

Nomad Power Solutions (NMAD) is larger, with a market capitalization of $47.15M compared with $46.20M for Milestone Pharmaceuticals (MIST).

Which stock has performed better over the past year, MIST or NMAD?

NMAD returned -40.60% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Milestone Pharmaceuticals and Nomad Power Solutions in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons